Ma1 Z, Niu1 J, Cao Y, et al. - The research was sought to ascertain the frequency of ‘Double-hit’ lymphoma (DHL) and ‘double-expression’ lymphoma (DEL) in diffuse large B-cell lymphoma (DLBCL) and their prognostic impacts in the era of cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab therapy. In this study, the data and tissues from 98 patients diagnosed with DLBCL were applied. They assembled formalin-fixed and paraffin-embedded tissues for immunohistochemistry (IHC) and interphase fluorescence in situ hybridization (FISH) analysis for MYC, BCL6, and BCL2 rearrangements. The study found that MYC/BCL2 DHL, MYC/BCL6 DHL, and MYC/BCL2 DEL are aggressive B cell lymphoma and individuals have a poor prognosis. For DHL and DEL, IPI and bone marrow involvement were independent prognostic factors. for survival, BCL2, BCL6 and MYC rearrangements translocation, expression concurrent rearrangements and coexpression were independent prognostic factors.